first trust dsip (Delta Sleep-Inducing Peptide) first trust dsip portfolio What

It accelerates the healing process by promoting angiogenesis (formation of new blood vessels) and improving oxygen supply to injured areas

BPC-157 and TB-500 protocols run on a similar frequency

If you are considering peptide therapy, our team of experts is here to guide you through every step of the process, ensuring you receive the best possible care tailored to your unique needs.

These results are directly comparable to what can be achieved through bariatric surgery

[3] For BPC-157 and other experimental peptides, the side effect profile is largely unknown due to lack of human clinical trials

Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges